In the winter of 1898, in a gaslit London parlour, a mother spooned a gleaming amber syrup into her coughing daughter’s mouth and felt reassured by the label: this was Bayer’s newest product, clinically tested, recommended by physicians, and bearing the clean, confident trade name Heroin.
The Cough Syrup That Contained Heroin
The man responsible for that label was Heinrich Dreser, head of pharmacological research at Bayer’s laboratory in Elberfeld, Germany. In August 1898, Dreser presented diacetylmorphine — the chemical compound his team had been refining — to the German Society of Naturalists and Physicians. His argument was precise and, by the standards of the day, genuinely compelling: the drug suppressed coughs powerfully, it calmed respiratory distress, and — crucially — it appeared to be a safer, less habit-forming substitute for morphine. He called it heroisch: heroic. The trade name wrote itself.
Bayer moved fast. Free samples were posted to physicians across Europe and North America. Within a year, advertisements for Heroin appeared in medical journals, sitting neatly alongside notices for Bayer’s other 1898 debut: aspirin. Two blockbusters, one year, one laboratory. The company’s confidence was not misplaced in the short term — both drugs worked, and both sold. The difference was that one of them would eventually become synonymous with catastrophe.
It is worth pausing on this: what Dreser launched was not fringe quackery. It was not the work of a travelling salesman hawking bottled mystery from a wagon. It was cutting-edge Victorian medicine, backed by one of the era’s most respected pharmaceutical houses, prescribed by trained doctors acting in good faith, and welcomed by a public that had every reason to trust the science arriving at their doorstep.
The World Dreser’s Science Grew From
To understand why nobody flinched, you need to understand the world Dreser was working in. The Victorian era — defined by the reign of Queen Victoria from June 20, 1837, until her death on January 22, 1901 — was sixty-three years of extraordinary transformation. Its final two decades, roughly 1880 to 1901, are what historians call the late Victorian era: the British Empire at its widest territorial reach, industrialisation at its most relentless, and science moving at a pace that felt almost supernaturally fast to people who had been born into a world of leeches and miasma theory.
Late Victorian daily life in the 1880s and 1890s was shaped, above all, by soot and sickness. Factory chimneys darkened the air over Britain’s cities; coal dust settled into lungs the way it settled onto windowsills — slowly, permanently. Tuberculosis, then called consumption, killed roughly one in four adults in Britain during the nineteenth century. The cough was not a minor domestic inconvenience. It was a sound that could mean death, and every mother who heard it in her child’s chest knew what it might mean. Into that fear, a powerful cough suppressant was not a luxury. It was mercy.
Medicine itself was in the middle of a revolution. Germ theory had overturned centuries of received wisdom within living memory. Anaesthesia had transformed surgery from a screaming ordeal into something survivable. Synthetic chemistry was producing compounds that seemed, each year, to push further into the territory of miracle. Yet regulation had not kept pace. Britain’s 1868 Pharmacy Act placed some restrictions on arsenic and opium sales, but patent medicines existed in an almost entirely free market, their claims checked by no one and contested by almost no one. The gap between Dreser’s laboratory bench and a family’s bedside cabinet was astonishingly, dangerously short.
It is also worth understanding what “late Victorian” meant in terms of geopolitical confidence. Britain governed roughly a quarter of the world’s land surface by the 1890s. The Great Exhibition of 1851 had established a cultural template — British and European industrial ingenuity as a progressive, civilising force — that had only hardened in the decades since. Science was not merely useful. It was ideologically central, a proof of the era’s own superiority over what had come before. That confidence shaped how pharmaceutical discoveries were received: not with scepticism, but with pride.
Cocaine Before Breakfast: The Tooth, the Throat, and the Surgery
Heroin arrived into a pharmaceutical culture that had already normalised one powerful alkaloid. Cocaine had been isolated from coca leaves in 1860, but it was Carl Koller’s 1884 demonstration of its use as a local anaesthetic in eye surgery that truly detonated its medical career. Within months of Koller’s paper, dentists across the late Victorian world were injecting cocaine into aching gums, and the response from patients was rapturous. A toothache in the 1880s was among the most common medical complaints in Britain, and extractions performed without effective pain relief were events people genuinely dreaded. Cocaine seemed close to miraculous, and dental suppliers began stocking it as routinely as they stocked their forceps.
Sigmund Freud, then a young Viennese neurologist with ambitions that outran his clinical evidence, published his 1884 monograph Über Coca recommending cocaine for morphine addiction, depression, and digestive complaints — and took it himself. His colleague Ernst von Fleischl-Marxow, whom Freud had encouraged to use cocaine to treat a morphine dependency, became severely addicted to cocaine instead. It is one of Victorian medicine’s darkest cautionary arcs, and it played out with terrible clarity, in plain sight, while the medical profession continued to celebrate the drug.
By the time Dreser was refining heroin at Bayer in the mid-1890s, cocaine had been normalised across medicine for a decade. The conceptual door was wide open: if one alkaloid could perform such feats, why not another? Dreser stepped through that door with the full confidence of a man whose professional world had, repeatedly, rewarded exactly that kind of confidence.
Laudanum in the Lace Cupboard: The Older Opium Culture
Before heroin, before cocaine’s dental triumphs, there was laudanum. Opium dissolved in alcohol, it was as ordinary a household item in late Victorian England as vinegar or camphor. It soothed teething babies. It calmed what physicians described as hysteria in women. It quieted the elderly and the restless. It was sold over chemists’ counters for pennies — and here is the oddly specific detail that the era’s ledgers preserve: in 1890s Britain, chemists’ sales books record laudanum sold in quantities as small as a halfpenny’s worth, meaning a working-class family could dose their children for the cost of a postage stamp.
Thomas De Quincey’s Confessions of an English Opium-Eater, published in 1821, had made opium addiction a known and widely discussed phenomenon decades before the late Victorian period began. Yet in the 1880s, Mrs Winslow’s Soothing Syrup — a preparation containing morphine — was still being advertised in family newspapers and administered to infants. The product promised rest for the child and relief for the mother, and it delivered on both counts, at a price that was not itemised on the label.
This was the pharmaceutical background noise of Victorian life against which Dreser’s heroin arrived. Not as a scandal. As an improvement. A modern, scientifically manufactured, clinically tested improvement on the old improvised opiate culture that had been running, largely unchallenged, for most of the century.
The class dimension of laudanum use deserves particular attention. Literary accounts — De Quincey, Wilkie Collins, even Elizabeth Barrett Browning’s private correspondence — give us the middle-class opium experience: reflective, articulate, documented. The working-class experience is preserved mainly in coroners’ records and chemists’ ledgers. Infant mortality inquests from the 1880s and 1890s return repeatedly to the same finding: a child given “quietness drops” or a proprietary soothing syrup who did not wake. The substance was the same across classes. The oversight, and the accountability, were not.
Why Doctors Believed It: The Logic of Late Victorian Medicine
It would be easy — and wrong — to dismiss the physicians who prescribed heroin as naive or negligent. Late Victorian medicine was not ignorant. It was operating at the frontier of what was known, and the lesson those doctors had learned, again and again throughout their careers, was that bold science saves lives. Germ theory had seemed outlandish; it turned out to be true. Anaesthesia had seemed reckless; it turned out to be transformative. Antiseptics had met fierce resistance; they had proved their case in the operating theatre. The intellectual habit of trusting new, well-sourced science was not foolishness. It was the correct response to recent history.
The addiction liability of opiates was understood in outline by the 1890s — which is precisely why Dreser’s central marketing claim was so effective with careful, ethical physicians rather than reckless ones. If heroin really was less habit-forming than morphine, that was not a minor commercial advantage. It was a genuine medical breakthrough. Dreser, by all accounts, believed this sincerely. The acetylation process that converted morphine into diacetylmorphine did change the compound’s behaviour in the body; what Dreser’s data could not yet show was the direction in which it changed. He had real evidence that it worked. He had no long-term addiction studies, because long-term addiction studies, as a methodology, barely existed.
What was life like in the late Victorian era for a general practitioner? Overworked, under-resourced, facing tuberculosis, influenza, industrial injuries, and chronic pain with a toolkit that, even at its 1890s best, was thin. A drug that suppressed coughs powerfully, came from a house as reputable as Bayer, and had been reviewed in the British Medical Journal was not something a conscientious doctor refused his patients. It was something he was relieved to offer them. That is the uncomfortable truth that sits at the centre of this story.
There is a structural point worth making here about the information environment of the 1890s. Bayer’s sample programme placed heroin directly in physicians’ hands before independent clinical assessment could accumulate. Positive reports circulated quickly through medical journals. Negative observations — patients returning with escalating dose requirements, withdrawal symptoms on cessation — took years to coalesce into a recognisable pattern, and longer still to be published in terms that contradicted the original claims. The commercial timeline and the scientific timeline ran at incompatible speeds, and commerce had the head start.
The Reckoning Arrives — Just After Victoria Dies
Queen Victoria died on January 22, 1901, closing sixty-three years of an era. The reckoning for its pharmaceutical legacy arrived in the years immediately after. Addiction crises driven by over-the-counter opiates and cocaine began generating legislative pressure that the free market in medicines could no longer deflect. The United States passed the Harrison Narcotics Act in 1914. Britain’s Dangerous Drugs Act followed in 1920. The era of the penny’s worth of laudanum and the free sample of heroin was closing, one statute at a time.
Dreser’s own trajectory is telling. He collected royalties from both aspirin and heroin during his years at Bayer — by some accounts the heroin royalties outpaced aspirin’s in the early years, which is the kind of historical footnote that lands like a stone in still water. He died in 1924, just as the full scale of heroin’s human cost was becoming impossible to argue away. Bayer quietly retired the Heroin trademark as the drug’s reputation collapsed beyond salvaging. The name, chosen to evoke heroisch — heroic, powerful — had become an irony too bleak to place on a label. Aspirin endured. The other 1898 launch did not.
The legislative response was itself shaped by anxieties that were not purely medical. In Britain, the 1916 Defence of the Realm Act regulations on cocaine were driven partly by concerns that recreational drug use was impairing the fighting efficiency of troops. In the United States, the Harrison Act was framed as a tax measure partly because a direct federal prohibition on medicines sat awkwardly with existing constitutional arrangements. The laws that emerged from the late Victorian pharmaceutical free-for-all were not always clean expressions of public health logic. They were political documents, negotiated under pressure, carrying the fingerprints of their moment. That, too, is part of the legacy.
The arc from late Victorian medicine to early twentieth-century drug law is not, finally, a story of evil confronted by good. It is a story of knowledge arriving too slowly to outrun commerce and genuine belief — which is a more disturbing story, and a more accurate one.
What It Tells Us About the Late Victorian World — and Our Own
The ease with which heroin, cocaine, and laudanum moved through Victorian daily life reveals a society that had placed something close to religious faith in industrial science — and not without reason. Vaccines, anaesthesia, and antiseptics had already performed genuine miracles within living memory. The trust was earned. The problem was that earned trust, once established, does not distinguish cleanly between the triumphs and the catastrophes that follow.
It was also, unavoidably, a class story. Wealthy patients received their cocaine in a physician’s surgery, in measured doses, with professional oversight. Working-class families bought laudanum from corner chemists for a halfpenny, dosed their children, and managed with what they had. The risks did not distribute equally. They rarely do.
The late Victorian pharmaceutical moment also offers a precise illustration of what happens when regulatory architecture fails to keep pace with industrial chemistry. The 1868 Pharmacy Act was written for a world of apothecaries dispensing known compounds in measured quantities. It was not written for a world in which a German corporation could manufacture a novel psychoactive substance at industrial scale, post free samples to thousands of physicians simultaneously, and have the product in domestic use within months. The law was not corrupt. It was simply obsolete before Dreser had finished his first synthesis.
Dreser threads all of it together — the ambition, the rigour, the blind spot, the marketing, the genuine belief, and the genuine harm. He was not a villain. He was an intelligent man working at the edge of what his era could see, moving faster than the knowledge he needed could travel. The most dangerous medical mistakes, history suggests with some insistence, are rarely made by villains. They are made by people like Heinrich Dreser: capable, confident, and certain that the science, this time, has finally arrived at something heroic.
Next time you see a cough syrup advertisement promising rapid relief, clinical validation, and the backing of a trusted pharmaceutical name, you are living in a world that was partly shaped by a Bayer chemist in 1898 — and by the patients, and the doctors, and the mothers with their amber spoons, who trusted him.
